NEXTDC (ASX:NXT) Record 667MW Contracted & A$2.2B Capital Plan
S4 hits 71% contracted as utilisation jumps 60% to 667MW
NextDC (ASX:NXT) has added 250MW…
- ASX: NTI
Neurotech International
Share Price and News
ASX BIG FOUR - LIVE SNAPSHOT
SELL
Whitehaven Coal
(ASX:WHC)
Paul Flynn
01/03/2026
$8.7m
BUY
Elixir Energy
(ASX:EXR)
Featured
SELL
Aspen Group
(ASX:APZ)
David Dixon
03/03/2026
$11.4m
BUY
Lovisa
(ASX:LOV)
Brett Blundy
04/03/2026
$6.8m
— Copmany Overview
About Neurotech International
Neurotech International is an Australian biotechnology company focused on developing and commercialising treatments for neurological and mental health conditions. The company is primarily working on NTI164, a cannabis-derived therapy aimed at treating paediatric neurological disorders such as Autism Spectrum Disorder (ASD), PANDAS/PANS, Rett Syndrome, and spastic cerebral palsy. Preclinical and clinical studies have vindicated not just that it can work, but that it addresses the underlying causes and not just symptoms.
NTI Company History
Neurotech was founded with a vision to address critical gaps in the treatment of neurological and mental health disorders. It acquired a Malta-based company (AAT Research) that had Mente Autism, a home-based device to relax kids’ minds and listed – events that occurred in 2016. While Mente was approved by the TGA, things fell apart in 2019 when it turned out that the founder of AAT Research did not have a Doctorate of Philosophy in neuroscience and he was terminated. Mente’s TGA registration was cancelled. NTI then pivoted to a unique cannabis strain that it thought could address autism (NTI-164). Now, it has expanded into Rett Syndrome, the same disorder Neuren is targeting. Phase I/II results were positive in both indications and the company is now targeting a larger trial that could see it receive regulatory approval, in autism.
- Free Report
Get Our Full ASX Stock Analysis Report
Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.
— Forward View
Future Outlook of Neurotech International (ASX: NTI)
Looking ahead, Neurotech International is well-placed to benefit from the need for efficacious neurological treatments. The company estimates it has a >US$10bn TAM across all indications and that’s assuming conservative pricing and a mere 1% market share. NTI is aiming for a provisional Australian determination and US Independent New Drug approval in the US by the end of 2025. It aims for TGA approval by the end of 2026, and for first revenues in 2027. Beforehand, the company hopes to have secured a partnering and/or licensing deal. As good as this sounds, the company’s fate is susceptible to regulators and the success of clinical trials. A lack of ability to stick with these timelines could be fatal to its future.
— Our Assessment
Is NTI a Good Stock to Buy?
Neurotech International presents an intriguing investment opportunity. It is attacking a neurological disorder (Rett) that made investors in Neuren rich, and it has the additional angle of bringing a medicinal cannabis drug to market. However, when considering whether to buy NTI stock, there are several important factors to keep in mind. The most important of which is whether or not it can stay on track with its timelines. NTI has significant growth potential, especially as its treatment moves closer to commercialisation, but it is also high risk.
— Our Stock Analysis
Related Articles
TSMC’s (NSDQ:TSM) Money Printer, March Revenue $13.1B, Margins Hit 58%
Record Margins, AI Demand Still Accelerating
TSMC (NSDQ:TSM) continues to show real pricing power. Demand…
ASML (NASDAQ:ASML) Q1 sales +15%, but system shipments slowed and stock fell 7%
Net orders beat revenue 1.2x, yet investors punished machine sales
ASML (NASDAQ:ASML) sits at the…
Michael Hill (ASX:MHJ): This Under Pressure Jewellery Outlet Is Trying To Position Itself As An AI P...
In this era, every company is trying to position itself as an AI play -…
Here are 5 Recent AI Acquisitions on the ASX! But Are They Just Hype?
This article explores 5 Recent AI Acquisitions on the ASX and whether or not these…
Amazon Is Making Returns from AI – A Whopping US$15bn In Just One Quarter!
It is that time of year again when Amazon releases its annual shareholder letter (along…
— Faq
Frequently Asked Questions
What is the dividend yield of Neurotech International?
Neurotech International does not currently offer a dividend, as it is focused on reinvesting earnings into its research and development efforts.
How does NTI compare to its peers?
NTI stands out from its peers in the biotechnology and medical cannabis sectors by focusing on cannabinoid-based treatments for neurological and mental health disorders. While many companies operate in similar spaces, NTI’s research partnerships and pipeline development set it apart.
What are the risks of investing in NTI?
The main risks include regulatory uncertainty surrounding medical cannabis, the outcome of clinical trials, and market competition. As with most biotechnology stocks, NTI’s future is tied to the success of its research and product approval.
What is the future outlook for NTI?
NTI’s future looks promising, with ongoing clinical trials and a growing market for medical cannabis treatments. The company’s expansion into international markets and strategic partnerships will be key drivers of its future growth.
Is Neurotech International a good investment?
For investors seeking exposure to the growing medical cannabis market, NTI presents an attractive growth opportunity. However, given its early-stage development and the inherent risks in the biotechnology sector, it may be more suitable for those with a higher risk tolerance.
Stay Sharp on the ASX
Weekly research. Independent analysis. No noise.
Free forever · Unsubscribe anytime
